Present

Scantox

Founded in 1977, Scantox is a market leading GLP (“Good Laboratory Practice”) accredited contract research organisation (”CRO”) located outside of Copenhagen.

Scantox provides pre-clinical research services, including regulatory in-vivo toxicology studies, exploratory in-vivo work and disease model development, all services that are critical to any drug development process. In addition, the Company performs various histology and pathology services. Scantox plays a vital role in the Nordic pharma and biotech community, where the Company has established deep relationships and enjoys a broad and loyal customer base, leveraging its strong track-record and more than 40 years of scientific experience.

Scantox’s strategy is to further strengthen and expand its geographic footprint as well as its service offering, to successfully support drug development efforts for both local and global companies in the pharma, biotech, and medical device sectors. Impilo’s investment in Scantox is part of an overarching strategy to drive further consolidation within pre-clinical drug development and drug discovery in Europe to build a larger group and streamline the value chain with a broader offering across adjacent service areas.

Responsible partner:Nicholas Hooge

Impilo Board Members:Nicholas Hooge

Industry:Pharma

Revenue 2019:DKK 109m

No of employees:c. 70 FTEs

CEO:Jeanet Løgsted

Acquisition Date:January 2021

Homepage: https://scantox.com/